DGAP-Adhoc: MediClin AG: Preliminary Group EBIT mainly burdened by one-off effects - preliminary Group sales meets forecast
DGAP-Ad-hoc: MediClin AG / Key word(s): Annual Results MediClin AG: Preliminary Group EBIT mainly burdened by one-off effects - preliminary Group sales meets forecast
22-Jan-2019 / 16:42 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Preliminary Group EBIT mainly burdened by one-off effects - preliminary Group sales meets forecast Offenburg, 22.01.2019 - MEDICLIN Aktiengesellschaft (MEDICLIN) informed today, that the preliminary operative Group EBIT will be between EUR 22 to 23 mill. and the preliminary Group EBIT burdened by one-off effects between EUR 14.5 - 15.5 mill. (previous year: 6.6 mill., adjusted EUR 26.7 mill.). Therefore MEDICLIN will not achieve the guidance for the Group EBIT in the amount of EUR 26 mill. The main reason for the decrease in results are possible additional expenses as well as provisions for personnel and other personnel expenses (one-off effects) in the amount of expected about EUR 7.5 mill. Regarding sales growth of the Group, this will probably reach 6 %. The disclosure of the preliminary figures for financial year 2018 will be on 22 February 2019 in the usual scale. The annual report 2018 will be available from 29 March 2019 onwards. The disclosed figures of this press release are subject to the final preparation of the consolidated financial statements, the final audit and the approval of the annual financial statements by the Supervisory Board.
22-Jan-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: | English | Company: | MediClin AG | | Okenstraße 27 | | 77652 Offenburg | | Germany | Phone: | +49 (0)781 488-326 | Fax: | +49 (0)781 488-184 | E-mail: | [email protected] | Internet: | www.mediclin.de | ISIN: | DE0006595101 | WKN: | 659510 | Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| End of Announcement | DGAP News Service |
768577 22-Jan-2019 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
609,08 |
645,11 |
673,09 |
659,86 |
673,14 |
704,70 |
730,07 |
EBITDA1,2 |
27,01 |
37,35 |
93,58 |
77,50 |
85,22 |
90,92 |
98,73 |
EBITDA-Marge3 |
4,43 |
5,79 |
13,90 |
11,74 |
12,66 |
12,90 |
|
EBIT1,4 |
6,62 |
15,06 |
22,41 |
0,15 |
11,56 |
19,52 |
12,72 |
EBIT-Marge5 |
1,09 |
2,33 |
3,33 |
0,02 |
1,72 |
2,77 |
1,74 |
Jahresüberschuss1 |
3,96 |
7,76 |
9,68 |
-0,04 |
1,49 |
9,72 |
-10,72 |
Netto-Marge6 |
0,65 |
1,20 |
1,44 |
-0,01 |
0,22 |
1,38 |
-1,47 |
Cashflow1,7 |
19,34 |
29,77 |
69,59 |
118,69 |
81,97 |
34,64 |
78,00 |
Ergebnis je Aktie8 |
0,08 |
0,16 |
0,20 |
-0,19 |
0,03 |
0,20 |
-0,23 |
Dividende8 |
0,05 |
0,05 |
0,05 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Mediclin |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
659510 |
2,860 |
Halten |
135,85 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
11,00 |
19,31 |
0,55 |
21,50 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,69 |
1,74 |
0,19 |
1,58 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
06.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
02.05.2024 |
31.07.2024 |
04.11.2024 |
26.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
10,77% |
5,11% |
4,38% |
-3,38% |
|
|